Use ENTRESTO™ in place of ACEis and ARBs for HFrEF patients1
ENTRESTO was studied in the largest HF trial ever conducted2
• Trial stopped early due to finding of significantly reduced risk of CV death and
the primary end point being met3
ENTRESTO has been proven superior to enalapril, a current
standard-of-care4 medication1
• Superiority vs enalapril, a standard-of-care ACEi therapy, across a range
of NYHA class II–IV patients with chronic HF and reduced ejection fraction
REDUCED RISK OF
CV DEATH OR FIRST
HF HOSPITALIZATION
VS ENALAPRIL1
P<0.0001
ABSOLUTE RISK
REDUCTION1
HR (95% CI): 0.80 (0.73, 0.87)
REDEFINE EXPECTATIONS IN HEART FAILURE
INDICATION
ENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
ENTRESTO is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB.
IMPORTANT SAFETY INFORMATION
WARNING: FETAL TOXICITY
• When pregnancy is detected, discontinue ENTRESTO as soon as possible
• Drugs that act directly on the renin-angiotensin system can cause injury and death
to the developing fetus
ENTRESTO is contraindicated in patients with hypersensitivity to any component. ENTRESTO is
contraindicated in patients with a history of angioedema related to previous angiotensin-converting
enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy.
ENTRESTO is contraindicated with concomitant use of ACE inhibitors. Do not administer within 36 hours
of switching from or to an ACE inhibitor. ENTRESTO is contraindicated with concomitant use of aliskiren
in patients with diabetes.
Angioedema: ENTRESTO may cause angioedema. Angioedema associated with laryngeal edema may be
fatal. ENTRESTO has been associated with a higher rate of angioedema in Black patients and in patients
with a prior his F